We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Epigenetic Profiling Could Refine Prognosis in Acute Myeloid Leukemia

By LabMedica International staff writers
Posted on 10 Jul 2026

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with heterogeneous biology that complicates prognostication and treatment selection. More...

Genetic testing clarifies many drivers, yet it often fails to explain divergent disease trajectories among patients. Understanding non-genetic mechanisms of gene regulation has become an important diagnostic frontier. A new study shows how epigenetic mapping can stratify AML into biologically meaningful groups.

Karolinska Institutet, in collaboration with Kyoto University, evaluated an epigenetic mapping approach that profiles how accessible DNA is within the cell nucleus to infer which genes may be active. The method captures chromatin accessibility, enabling classification based on gene regulatory states rather than DNA sequence changes. Researchers assessed regulatory patterns to delineate molecular programs that underlie AML heterogeneity and clinical behavior.

The investigation analyzed samples from 1,563 patients in Sweden and Japan. Using measurements of DNA accessibility, the team divided AML into 16 groups with distinct molecular and biological characteristics. The study integrated multiple data types, including gene expression, DNA methylation, and single-cell analyses, to define each group’s patterns of gene regulation, cell differentiation, and disease progression.

Several epigenetically defined groups were more closely associated with patient survival than existing classification systems, indicating added prognostic value. Drug-response profiling across 250 agents revealed group-specific differences in sensitivity that aligned with the epigenetic categories. The authors noted that these findings, published in Nature on July 8, 2026, do not replace current genetics-based systems but can complement them, and that additional studies are needed to validate the results and clarify clinical use.

“Our results show that, based on epigenetic analyses, leukemia can be divided into new biologically relevant subgroups that provide more information than genetic analyses alone,” said Sören Lehmann, professor at the Department of Medicine, Huddinge, Karolinska Institutet.

Related Links
Karolinska Institutet
Kyoto University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Platelet Function Analyzer
PL-12
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.